Notably, ETS2 was discovered to be downregulated in various cancers, such as THCA, bladder cancer (BLCA), diffuse large B-cell lymphoma (DLBC), glioblastoma multiforme (GBM), and breast cancer (BRCA), with the most pronounced downregulation observed in THCA (Figs 4A, 4B). Here, ETS2 is linked to urinary bladder cancer.